BR112014025740A2 - Vaccines and Methods to Treat Lyme Disease in Dogs - Google Patents

Vaccines and Methods to Treat Lyme Disease in Dogs

Info

Publication number
BR112014025740A2
BR112014025740A2 BR112014025740A BR112014025740A BR112014025740A2 BR 112014025740 A2 BR112014025740 A2 BR 112014025740A2 BR 112014025740 A BR112014025740 A BR 112014025740A BR 112014025740 A BR112014025740 A BR 112014025740A BR 112014025740 A2 BR112014025740 A2 BR 112014025740A2
Authority
BR
Brazil
Prior art keywords
dogs
vaccines
lyme disease
methods
immunogenic composition
Prior art date
Application number
BR112014025740A
Other languages
Portuguese (pt)
Inventor
Earnhart Christopher
J Millership Jason
F M Meeus Patrick
Thomas Marconi Richard
M Lohse Robert
Xu Zach
Original Assignee
Univ Virginia Commonwealth
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth, Zoetis Llc filed Critical Univ Virginia Commonwealth
Publication of BR112014025740A2 publication Critical patent/BR112014025740A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “vacinas e métodos para tratar a doença de lyme em cães” a presente invenção fornece uma composição imunogênica que compreende um fragmento antigênico da proteína ospa de borrelia burgdorferi e uma proteína quimérica contendo fragmentos antigênicos de diferentes filotipos da proteína ospc de borrelia burgdorferi. as vacinas que incorporam a composição imunogênica da invenção, bem como os métodos para prevenir a doença de lyme em cães e / ou proteger os cães de contrair a doença de lyme ao usar as vacinas, são também fornecidos.Abstract Vaccines and Methods for Treating Lyme Disease in Dogs The present invention provides an immunogenic composition comprising an antigenic fragment of the ospa protein from Borrelia burgdorferi and a chimeric protein containing antigenic fragments from different phylotypes of the ospc protein from Borrelia burgdorferi. vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing lyme disease in dogs and/or protecting dogs from contracting lyme disease when using the vaccines, are also provided.

BR112014025740A 2012-04-18 2013-04-18 Vaccines and Methods to Treat Lyme Disease in Dogs BR112014025740A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261635031P 2012-04-18 2012-04-18
PCT/US2013/037063 WO2013158818A2 (en) 2012-04-18 2013-04-18 Vaccines and methods to treat lyme disease in dogs

Publications (1)

Publication Number Publication Date
BR112014025740A2 true BR112014025740A2 (en) 2017-07-04

Family

ID=48193279

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025740A BR112014025740A2 (en) 2012-04-18 2013-04-18 Vaccines and Methods to Treat Lyme Disease in Dogs

Country Status (10)

Country Link
EP (1) EP2838555A2 (en)
JP (1) JP2015514776A (en)
CN (1) CN104379164A (en)
AR (1) AR090726A1 (en)
AU (1) AU2013249229A1 (en)
BR (1) BR112014025740A2 (en)
CA (1) CA2870179C (en)
EA (1) EA201491668A1 (en)
UY (1) UY34745A (en)
WO (1) WO2013158818A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204404A4 (en) 2014-10-08 2018-06-06 Virginia Commonwealth University Stage specific diagnostic antigens, assay and vaccine for lyme disease
US11883476B2 (en) 2017-12-04 2024-01-30 Intervet Inc. Canine lyme disease vaccine
CN110483624B (en) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 Borrelia garinii OspA protein C-terminal peptide segment and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
ATE181572T1 (en) * 1991-08-15 1999-07-15 Smithkline Beecham Biolog OSPA PROTEINS OF BORRELIA BURGDORFERI SUBGROUPS, GENES CODING FOR THEM AND VACCINES
PT1100922E (en) 1998-07-31 2008-05-30 Gundersen Lutheran Medical Fou Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
WO2009135118A2 (en) * 2008-05-02 2009-11-05 Virginia Commonwealth University Lyme disease vaccine
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
US8808705B2 (en) * 2010-10-20 2014-08-19 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen

Also Published As

Publication number Publication date
EP2838555A2 (en) 2015-02-25
EA201491668A1 (en) 2015-08-31
JP2015514776A (en) 2015-05-21
AR090726A1 (en) 2014-12-03
CN104379164A (en) 2015-02-25
WO2013158818A2 (en) 2013-10-24
AU2013249229A1 (en) 2014-10-23
CA2870179A1 (en) 2013-10-24
WO2013158818A3 (en) 2014-04-17
CA2870179C (en) 2018-09-04
UY34745A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
BR112017014258A2 (en) anti-cd47 antibodies and uses thereof
AR090465A1 (en) SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFARMACO
BR112014028476A2 (en) immunogenic fragment of a polypeptide, isolated polynucleotide, immunogenic pharmaceutical composition, methods for treating an infection, for generating an immune response in a subject, and for immunizing a subject
BR112014008294A2 (en) anti c-met antibody and uses of it
BR112015012933A2 (en) bcma antigen binding proteins
ECSP15025845A (en) ANTI-CEACAM5 ANTIBODIES AND USES OF THEM
BR112015022191A8 (en) heteroaryl compounds and uses thereof
BR112017002761A2 (en) anti-methanogenic compositions and uses thereof
BR112016013493A2 (en) nucleic acid molecule, composition, vaccine, and methods for preventing a disease in an individual in need thereof and for treating a disease in an individual in need thereof
CL2014001994A1 (en) Synthetic apeline mimetic polypeptide for treatment and heart failure; pharmaceutical composition comprising said polypeptide.
BR112014023937A2 (en) pharmaceutical composition, pharmaceutical combination and treatment method
CL2015003343A1 (en) Pharmaceutical composition comprising a modified therapeutic agent based on hemoglobin, for the treatment to treat cancer, and diagnostic images.
BR112019012796A2 (en) antineuropillin antigen binding proteins and methods of use thereof
CY1120772T1 (en) Mutated OspA FRAGMENTS AND RELATED METHODS AND USES
BR112014021104A2 (en) methods and compositions for the treatment of huntington's disease
BR112014021531A2 (en) compound, pharmaceutical composition and uses thereof
BR112012027315A8 (en) chimeric polypeptide, composition, chimeric nucleic acid molecule, vector, host cell, polypeptide production process, combined vaccine, and methods for inducing an immune response and for preventing or treating an infection or disease
BR112012005860A2 (en) peptides isolated from spider venom, and uses thereof
BR112017004197A2 (en) Dengue virus disease vaccine compositions
BR112015032763A2 (en) soluble cd33 to treat myelodysplastic syndromes (mds)
BR112014031512A2 (en) cosmetic composition and method for cosmetic treatment.
AR093620A1 (en) BMP-6 ANTIBODIES
MX369195B (en) Mutant fragments of ospa and methods and uses relating thereto.
BR112015008745A2 (en) method for treating spinal cord injury using hmgb1 fragment
BR112016029024A2 (en) texaphyrin-pt (iv) conjugates and compositions for use in overcoming platinum resistance

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]